Internal and Emergency Medicine

, Volume 4, Issue 4, pp 297–308 | Cite as

The acute porphyrias: a diagnostic and therapeutic challenge in internal and emergency medicine

  • Paolo Ventura
  • Maria Domenica Cappellini
  • Emilio Rocchi
IM - Review

Abstract

The porphyrias are a heterogeneous group of metabolic diseases resulting from a variable catalytic defect of one of the eight enzymes involved in the heme biosynthesis pathway; they are mostly inherited diseases, but in some circumstances the metabolic disturbance may be acquired. The specific patterns of tissue overproduction (and hence accumulation and excretion) of toxic heme precursors, associated with each enzymatic deficiency, are responsible for the characteristic biochemical and clinical features of each of these diseases. Moreover, even in the presence of a specific inherited enzymatic defect, many different environmental factors (such as drugs, calorie restriction, hormones, sunlight exposition, infections, etc.) often play a key role in triggering the clinical expression of the various forms of porphyrias. The porphyrias are often misdiagnosed diseases, due their multiform clinical manifestations, able to mimic many other more common diseases. For this reason, many different specialists, such as surgeons, psychiatrists, gastroenterologists, neurologists, emergency physicians and dermatologists may be variably involved in the diagnostic process, especially for the forms presenting with acute and life-threatening clinical features. According to the clinical features, the porphyrias can be classified into neuropsychiatric (characterized by neurovisceral crises involving autonomic and central nervous system but also the liver and the kidney with possible consequences in terms of neurological, psychic, cardiac, respiratory, liver and kidney functions), dermatological (mostly presenting with cutaneous lesions due to photosensitivity), and mixed forms. From a strictly clinical point of view, porphyrias presenting with neurovisceral attacks are also referred as acute porphyrias: they are the object of the present review. An accurate diagnosis of acute porphyria requires knowledge and the use of correct diagnostic tools, and it is mandatory to provide a more appropriate therapeutic approach and prevent the use of potentially unsafe drugs, able to severely precipitate these diseases, especially in the presence of life-threatening symptoms. To date, availability of a relatively stable haem preparation (haem arginate) has significantly improved the treatment outcome of acute porphyric attacks, so the knowledge about the diagnosis and the management of these diseases may be relevant for physicians working in internal medicine, neurology and emergency units.

Keywords

Heme Acute porphyrias Heme arginate Neurovisceral crises Porphyric acute attack 

Notes

Conflict of interest statement

The authors declare that they have no conflict of interest related to the publication of this manuscript.

References

  1. 1.
    Kauppinen R (2005) Porphyrias. Lancet 365:241–252PubMedGoogle Scholar
  2. 2.
    Ventura E, Rocchi E (2001) Le Porfirie. In: Guarini G, Fiorelli G, Malliani A, Violi E, Volpe M (eds) Teodori 2000. Trattato di Medicina Interna.Società Editrice Universo, Roma, pp 2301–2334Google Scholar
  3. 3.
    Anderson KE, Sassa S, Bishop DF, Desnick RJ (2001) Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. In: Scriver CR, Beaudet A, Sly WS, Valle D (eds) The metabolic and molecular basis of inherited diseases. McGraw-Hill, New York, pp 2991–3062Google Scholar
  4. 4.
    Phillips JD, Bergonia HA, Reilly CA et al (2007) A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc Natl Acad Sci USA 104:5079–5084PubMedCrossRefGoogle Scholar
  5. 5.
    Rigal JC, Blanloeil Y (2002) Anaesthesia and porphyria. Minerva Anestesiol 68:326–331PubMedGoogle Scholar
  6. 6.
    Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R (2003) Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol 39:620–627PubMedCrossRefGoogle Scholar
  7. 7.
    Badminton MN, Elder GH (2005) Molecular mechanisms of dominant expression in porphyria. J Inherit Metab Dis 28:277–286PubMedCrossRefGoogle Scholar
  8. 8.
    Gouya L, Puy H, Robreau AM et al (2004) Modulation of penetrance by the wild-type allele in dominantly inherited erythropoietic protoporphyria and acute hepatic porphyrias. Hum Genet 114:256–262PubMedCrossRefGoogle Scholar
  9. 9.
    Kauppinen R (2004) Molecular diagnostics of acute intermittent porphyria. Expert Rev Mol Diagn 4:243–249PubMedCrossRefGoogle Scholar
  10. 10.
    Bonkovsky HL, Barnard GF (1998) Diagnosis of porphyric syndromes: a practical approach in the era of molecular biology. Semin Liver Dis 18:57–65PubMedCrossRefGoogle Scholar
  11. 11.
    de Rooij WM, Edixhoven A, Wilson JH (2003) Porphyria: a diagnostic approach. In: Kadish KM, Smith KM, Guillard R (eds) The porphyrin handbook. Elsevier, St Louis, pp 211–245Google Scholar
  12. 12.
    Grob U, Puy H, Jacob K et al (2006) Biochemical compared to molecular diagnosis in acute intermittent porphyria. J Inherit Metab Dis 29:157–161PubMedCrossRefGoogle Scholar
  13. 13.
    Elder GH, Hift RJ, Meissner PN (1997) The acute porphyrias. Lancet 349:1613–1617PubMedCrossRefGoogle Scholar
  14. 14.
    Solinas C, Vajda FJ (2008) Neurological complications of porphyria. J Clin Neurosci 15:263–268PubMedCrossRefGoogle Scholar
  15. 15.
    Kirsch RE, Meissner PN, Hift RJ (1998) Variegate porphyria. Semin Liver Dis 18:33–41PubMedCrossRefGoogle Scholar
  16. 16.
    Martasek P (1998) Hereditary coproporphyria. Semin Liver Dis 18:25–32PubMedCrossRefGoogle Scholar
  17. 17.
    Sassa S (1998) ALAD porphyria. Semin Liver Dis 18:95–101PubMedCrossRefGoogle Scholar
  18. 18.
    Frith D, Yeung K, Thrush S et al (2005) Lead poisoning—a differential diagnosis for abdominal pain. Lancet 366:2146PubMedCrossRefGoogle Scholar
  19. 19.
    Usalan C, Erdem Y, Altun B et al (1996) Severe hyponatremia due to SIADH provoked by acute intermittent porphyria. Clin Nephrol 45:418PubMedGoogle Scholar
  20. 20.
    Crimlisk HL (1997) The little imitator–porphyria: a neuropsychiatric disorder. J Neurol Neurosurg Psychiatry 62:319–328PubMedCrossRefGoogle Scholar
  21. 21.
    Tishler PV, Woodward B, O’Connor J et al (1985) High prevalence of intermittent acute porphyria in a psychiatric patient population. Am J Psychiatry 142:1430–1436PubMedGoogle Scholar
  22. 22.
    Hultdin J, Schmauch A, Wikberg A et al (2003) Acute intermittent porphyria in childhood: a population-based study. Acta Paediatr 92:562–568PubMedCrossRefGoogle Scholar
  23. 23.
    Kauppinen R, von und zu Fraunberg M (2002) Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families. Clin Chem 48:1891–1900PubMedGoogle Scholar
  24. 24.
    Kanaan C, Veille JC, Lakin M (1989) Pregnancy and acute intermittent porphyria. Obstet Gynecol Surv 44:244–249PubMedCrossRefGoogle Scholar
  25. 25.
    Deybach JC, Badminton M, Puy H et al (2006) European porphyria initiative (EPI): a platform to develop a common approach to the management of porphyrias and to promote research in the field. Physiol Res 55(Suppl 2):S67–S73PubMedGoogle Scholar
  26. 26.
    Thadani H, Deacon A, Peters T (2000) Diagnosis and management of porphyria. BMJ 320:1647–1651PubMedCrossRefGoogle Scholar
  27. 27.
    Andersson C, Lithner F (1994) Hypertension and renal disease in patients with acute intermittent porphyria. J Intern Med 236:169–175PubMedCrossRefGoogle Scholar
  28. 28.
    Andant C, Puy H, Bogard C et al (2000) Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. J Hepatol 32:933–939PubMedCrossRefGoogle Scholar
  29. 29.
    de Verneuil H, Ged C, Boulechfar S, Moreau-Gaudry F (1995) Porphyrias: animal models and prospects for cellular and gene therapy. J Bioenerg Biomembr 27:239–248PubMedCrossRefGoogle Scholar
  30. 30.
    Rocchi E, Ventura P, Ronzoni A et al (2004) Pro-oxidant and antioxidant factors in acute intermittent porphyria: family studies. J Inherit Metab Dis 27:251–266PubMedCrossRefGoogle Scholar
  31. 31.
    Lindberg RL, Martini R, Baumgartner M et al (1999) Motor neuropathy in porphobilinogen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria. J Clin Invest 103:1127–1134PubMedCrossRefGoogle Scholar
  32. 32.
    Seth AK, Badminton MN, Mirza D et al (2007) Liver transplantation for porphyria: who, when, and how? Liver Transpl 13:1219–1227PubMedCrossRefGoogle Scholar
  33. 33.
    Shanley BC, Neethling AC, Percy VA, Carstens M (1975) Neurochemical aspects of porphyria: studies on the possible neurotoxicity of delta-aminolaevulinic acid. S Afr Med J 49:576–580PubMedGoogle Scholar
  34. 34.
    Minder EI (1986) Measurement of 5-aminolaevulinic acid by reversed phase HPLC and fluorescence detection. Clin Chim Acta 161:11–18PubMedCrossRefGoogle Scholar
  35. 35.
    Hift RJ, Davidson BP, van der Hooft C et al (2004) Plasma fluorescence scanning and fecal porphyrin analysis for the diagnosis of variegate porphyria: precise determination of sensitivity and specificity with detection of protoporphyrinogen oxidase mutations as a reference standard. Clin Chem 50:915–923PubMedCrossRefGoogle Scholar
  36. 36.
    Erlandsen EJ, Jorgensen PE, Markussen S, Brock A (2000) Determination of porphobilinogen deaminase activity in human erythrocytes: pertinent factors in obtaining optimal conditions for measurements. Scand J Clin Lab Invest 60:627–634PubMedCrossRefGoogle Scholar
  37. 37.
    Campbell BC, Brodie MJ, Thompson GG et al (1977) Alterations in the activity of enzymes of haem biosynthesis in lead poisoning and acute hepatic prophyria. Clin Sci Mol Med 53:335–340PubMedGoogle Scholar
  38. 38.
    Floderus Y, Sardh E, Moller C et al (2006) Variations in porphobilinogen and 5-aminolevulinic acid concentrations in plasma and urine from asymptomatic carriers of the acute intermittent porphyria gene with increased porphyrin precursor excretion. Clin Chem 52:701–707PubMedCrossRefGoogle Scholar
  39. 39.
    Thunell S (2006) (Far) Outside the box: genomic approach to acute porphyria. Physiol Res 55(Suppl 2):S43–S66PubMedGoogle Scholar
  40. 40.
    Cappellini MD, Martinez di Montemuros F, Di Pierro E, Fiorelli G (2002) Hematologically important mutations: acute intermittent porphyria. Blood Cells Mol Dis 28:5–12PubMedCrossRefGoogle Scholar
  41. 41.
    Elder GH, Hift RJ (2001) Treatment of acute porphyria. Hosp Med 62:422–425PubMedGoogle Scholar
  42. 42.
    Kauppinen R, Mustajoki P (1992) Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine (Baltimore) 71:1–13Google Scholar
  43. 43.
    Handschin C, Lin J, Rhee J et al (2005) Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. Cell 122:505–515PubMedCrossRefGoogle Scholar
  44. 44.
    Schuurmans MM, Hoffmann F, Lindberg RL, Meyer UA (2001) Zinc mesoporphyrin represses induced hepatic 5-aminolevulinic acid synthase and reduces heme oxygenase activity in a mouse model of acute hepatic porphyria. Hepatology 33:1217–1222PubMedCrossRefGoogle Scholar
  45. 45.
    Krauss GL, Simmons-O’Brien E, Campbell M (1995) Successful treatment of seizures and porphyria with gabapentin. Neurology 45:594–595PubMedGoogle Scholar
  46. 46.
    Anderson KE, Spitz IM, Sassa S et al (1984) Prevention of cyclical attacks of acute intermittent porphyria with a long-acting agonist of luteinizing hormone-releasing hormone. N Engl J Med 311:643–645PubMedCrossRefGoogle Scholar
  47. 47.
    Cohen SM (2001) Lead poisoning: a summary of treatment and prevention. Pediatr Nurs 27(125/126):129–130Google Scholar
  48. 48.
    Pimstone NR (2005) Roles and pitfalls of transplantation in human porphyria. Liver Transpl 11:1460–1462PubMedCrossRefGoogle Scholar
  49. 49.
    Sardh E, Rejkjaer L, Andersson DE, Harper P (2007) Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion. Clin Pharmacokinet 46:335–349PubMedCrossRefGoogle Scholar
  50. 50.
    Yasuda M, Domaradzki ME, Armentano D et al (2007) Acute intermittent porphyria: vector optimization for gene therapy. J Gene Med 9:806–811PubMedCrossRefGoogle Scholar

Copyright information

© SIMI 2009

Authors and Affiliations

  • Paolo Ventura
    • 1
  • Maria Domenica Cappellini
    • 2
  • Emilio Rocchi
    • 1
  1. 1.Department of Medicines and Medical Specialties, Ambulatorio delle Porfirie e delle Malattie da Disturbo del Metabolismo degli AminoacidiUniversity of Modena and Reggio EmiliaModenaItaly
  2. 2.Department of Internal Medicine, Policlinico Foundation IRCCSUniversity of MilanMilanItaly

Personalised recommendations